secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001104659-23-030127
Event type: debt
Sentiment:  neutral
Materiality: 0.15
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MTAC amends term sheet with Magnetar, increasing expense reimbursement cap to $600K
--------------------------------------------------------------------------------

- Amendment raises Magnetar's expense reimbursement cap from $300,000 to $600,000 for the proposed $50M convertible note financing.
- Notes are 8.0% senior secured convertible notes concurrent with the TriSalus business combination.
- Financing is contingent on closing of the business combination with TriSalus Life Sciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923030127/0001104659-23-030127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923030127/tm238778d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-030127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer